Search

A team of researchers from MSK and Weill Cornell Medicine is expanding the understanding of how a decades-old treatment for bladder cancer works — an understanding that could help improve the effectiveness of immunotherapies more broadly.

… Thursday, May 29, 2025 More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat early-stage bladder cancer. Now, a team of researchers from Memorial Sloan Kettering Cancer

Electronic nose (e-nose) technology identified early-stage lung cancer with high reliability in a prospective observational clinical trial conducted at Memorial Sloan Kettering Cancer Center (MSK).

… Friday, June 7, 2024 Electronic nose (e-nose) technology identified early-stage lung cancer with high reliability in a prospective observational clinical trial conducted at Memorial Sloan Kettering Cancer Center (MSK). E-nose diagnostic predictions agreed with histopathological results in 86% of 100

Researchers find an epigenetic role in how breast cancer tumors develop resistance to treatment.

… Thursday, March 23, 2017 Summary Many breast cancers rely on a disease pathway called PI3K, so drugs have been developed to inhibit this pathway. However, after responding initially to PI3K inhibitors, these tumors often activate another pathway, called ER, to begin growing again. A new finding reveals

Read about the 26th annual bone marrow transplant (BMT) Thrivers event, which took place on November 17, 2021.

… Friday, November 19, 2021 It was a highly anticipated reunion, and hard-won: Memorial Sloan Kettering Cancer Center’s 26th annual bone marrow transplant (BMT) Thrivers event celebrated survivors and the MSK care teams who supported them throughout their journeys. Participants hailed from far and wide

Discover how cyclist Stacia Smart turned her grief into purpose after her boyfriend died of a brain tumor.

… Friday, January 1, 2021 Bright, athletic, gregarious, and kind, Owen Strong was enjoying a quintessential life in Manhattan. Living with college friends from Tufts, he was working in the family real estate business and recording songs with his band, the Evening Fools. Then, in February 2018, at age 28

It’s not every day that scientists discover a new part of the cell. Two biologists from the Sloan Kettering Institute just did.

… Thursday, November 15, 2018 Summary Scientists at the Sloan Kettering Institute have discovered a new organelle. The finding challenges longstanding ideas about cell structure. Many people probably remember cell organelles from high school biology. Mitochondria are a cell’s “energy factories.” The nucleus

Learn how a novel drug is showing promise against lung and pancreatic cancer in early clinical trials by targeting the KRAS G12D mutation with a KRAS degrader.

… Wednesday, March 25, 2026 A new drug is showing promise in lung and pancreatic cancers — two of the most aggressive forms of cancer — by targeting one of the most common cancer-driving mutations. Setidegrasib, formerly known as ASP3082, tags and destroys the cancer-causing protein produced by the KRAS

… Thursday, March 12, 2009 Student Research Eric Alonzo Eric Alonzo Recent publications from our students. Eric Alonzo Kovalovsky D, Uche OU, Eladad S, Hobbs RM, Yi W, Alonzo E, Chua K, Eidson M, Kim HJ, Im JS, Pandolfi PP, Sant’Angelo DB. The BTB-zinc finger transcriptional regulator PLZF controls the

A new study from Memorial Sloan Kettering Cancer Center (MSK) provides important insights into cancer metastasis.  

… Thursday, February 3, 2022 New findings from researchers at Memorial Sloan Kettering Cancer Center (MSK), and published today in the journal Cell , support an emerging framework in cancer science that views metastasis as not primarily driven by genetic mutations, but rather by epigenetic changes that

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments:

… Monday, October 31, 2022 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Luis Diaz Luis Diaz Jr. Recognized with a 2022 El Award by New York’s El Diario Luis Alberto Diaz, Jr., MD , medical oncologist, Head Division of Solid Tumor Oncology, and Grayer Family